AKRO Akero Therapeutics Inc
Price (delayed)
$25.62
Market cap
$1.78B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.44
Enterprise value
$1.5B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 29% year-on-year but it is down by 6% since the previous quarter
AKRO's net income has shrunk by 77% YoY and by 14% QoQ
AKRO's debt is up by 39% year-on-year
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
69.43M
Market cap
$1.78B
Enterprise value
$1.5B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$200.17M
EBITDA
-$199.92M
Free cash flow
-$190.94M
Per share
Balance sheet
Liquidity
EPS
-$3.44
Free cash flow per share
-$2.76
Book value per share
$11.54
Revenue per share
$0
TBVPS
$12.51
Total assets
$865.04M
Total liabilities
$66.98M
Debt
$35.64M
Equity
$798.07M
Working capital
$744.84M
Debt to equity
0.04
Current ratio
24.89
Quick ratio
24.39
Net debt/EBITDA
1.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.3%
Return on equity
-29.6%
Return on invested capital
-51%
Return on capital employed
-24%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
-0.47%
1 week
-2.59%
1 month
3.56%
1 year
-48.11%
YTD
9.72%
QTD
9.21%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$234.18M
Net income
-$204.18M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has plunged by 86% YoY and by 15% from the previous quarter
AKRO's net income has shrunk by 77% YoY and by 14% QoQ
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 38% YoY and by 7% QoQ
The stock's P/B is 46% below its 5-year quarterly average of 4.1 and 18% below its last 4 quarters average of 2.7
AKRO's equity is up by 29% year-on-year but it is down by 6% since the previous quarter
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has surged by 54% YoY and by 11% QoQ
Akero Therapeutics's return on equity has decreased by 6% QoQ and by 2.1% YoY
The ROA has contracted by 6% from the previous quarter and by 3.4% YoY
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
The total liabilities is up by 41% year-on-year
The company's total assets rose by 30% YoY but it fell by 5% QoQ
AKRO's debt is 96% smaller than its equity
AKRO's debt is up by 39% year-on-year
AKRO's equity is up by 29% year-on-year but it is down by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.